Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators

Area of Science:

• Endocrinology
• Pharmacology
• Women's Health

Background:

• Selective estrogen receptor modulators (SERMs) are non-steroidal agents with tissue-specific estrogenic and anti-estrogenic effects.
• Existing SERMs like tamoxifen and raloxifene have demonstrated efficacy in breast cancer, osteoporosis, and menopausal symptom management.
• The development of novel SERMs and estrogen-based therapies aims to optimize therapeutic outcomes while minimizing adverse effects.

Purpose of the Study:

• To evaluate the efficacy and safety of a tissue-selective estrogen complex (CEE/BZA) in postmenopausal women.
• To assess the impact of CEE/BZA on vasomotor symptoms, vulvovaginal atrophy, bone mineral density, and breast health.
• To investigate the endometrial effects and safety profile of CEE/BZA compared to placebo.

Main Methods:

• The study analyzed data from the Selective Estrogen Menopause and Response to Therapy (SMART) trials.
• Participants received conjugated equine estrogens (CEE) 0.45 mg combined with bazedoxifene (BZA) 20 mg.
• Outcomes were assessed over up to two years, including symptom improvement, bone density, and breast/endometrial safety.

Main Results:

• CEE/BZA significantly improved moderate to severe vasomotor symptoms and vulvovaginal atrophy.
• The treatment effectively prevented bone loss at the lumbar spine and total hip.
• CEE/BZA demonstrated neutrality regarding breast tenderness and density, with breast cancer incidence similar to placebo. Endometrial safety was confirmed, with hyperplasia and cancer rates comparable to placebo.

Conclusions:

• The combination of conjugated equine estrogens and bazedoxifene (CEE/BZA) is an effective treatment for menopausal vasomotor symptoms and prevention of bone loss.
• CEE/BZA offers a favorable safety profile, showing no adverse effects on the breast and providing endometrial protection.
• This therapy represents a valuable option for managing menopausal symptoms and associated bone loss in postmenopausal women.